Nutrinia is a privately-held Israeli company which has developed drug products to treat acute to chronic intestinal failure based on its proprietary Oral Insulin technology. These drug products will treat rare diseases of the gastrointestinal tract and impact short- and long-term morbidities of pre-term infants, children, and adults.
Nutrinia has received orphan drug designation from the FDA for its short bowel syndrome drug.
On December 2014, Nutrinia has announced the closing of its Series C investment round. The $12 million investment was led jointly by internationally renowned investors OrbiMed, Jacobs Investment Company and Pontifax.
Funds from the round will be used to advance two multinational clinical studies to support registration of NTRA-2112 for treating pre-term infants and NTRA-9620 for treating Short Bowel Syndrome in the EU and the United States.